Deans' stroke musings: Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, June 5, 2025

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Describing a problem with NO solution is grounds for firing! Totally useless! Your mentors and senior researchers need to be fired also!

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

bySiwen LiuandAlex Chan

June 4, 2025

in Chronic Disease, Neurology

Reading Time: 2 mins read

1. Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) was independently associated with early cognitive impairment in patients with mild acute ischemic stroke.

Evidence Rating Level: 3 (Average)

Patients with acute ischemic stroke (AIS) commonly exhibit early cognitive impairment, which adversely impacts their quality of life and functional recovery. Dyslipidemia is an independent risk factor for AIS and plays an important role in cognitive impairment. Although evidence suggests that non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is more effective than traditional lipid parameters in predicting the risk of various cardiometabolic conditions, limited research exists on its relationship with early cognitive function in patients with AIS. This study thus examined the association between NHHR and early cognitive impairment in patients with AIS. This cross-sectional study included patients with AIS admitted to a hospital in China between January 2023 and January 2025. Cognitive function was evaluated within two weeks of acute cerebral infarction using the Mini-Mental State Examination (MMSE), with cognitive impairment determined by education-stratified thresholds. NHHR was calculated as total cholesterol—HDL-C)/HDL-C. Patients were stratified by NHHR into quartiles: Q1 (0.544–2.072), Q2 (2.072–2.904), Q3 (2.904–3.918), Q4 (3.918–15.591). Out of the 817 patients included in the study, 473 had cognitive impairment (mean age [SD] = 66.12 [9.62] years, male [%] = 312 [65%]) and 344 had normal cognition (mean age [SD] = 59.54 [9.77] years, male [%] = 234 [68%]). There was a dose-response relationship between NHHR quartiles and the incidence of cognitive impairment, with rates increasing from 51.7% in Q1 to 63.7% in Q4 (trend test P = 0.021). Multivariate regression analysis revealed each unit increase in NHHR was associated with a 13.2% increased risk of cognitive impairment (OR = 1.13, 95% confidence interval (CI) 1.02–1.25, P = 0.018). Overall, this study found NHHR to be a risk factor for early cognitive impairment in patients with AIS, highlighting its importance as a potential biomarker for cognitive decline in this population. Future longitudinal studies are needed to confirm these findings.

Click to read the study in EJMR